Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency

L. Casale, H. Gold, C. Schechter, A. Naficy, J. R. Masci

Research output: Contribution to journalArticle

13 Scopus citations


Study Objective: To determine the relationship between the degree of immune deficiency and the risk of Pneumocystis carinii pneumonia (PCP) among HIV-infected patients receiving inhaled pentamidine prophylaxis. Design: Retrospective chart review. Setting: AIDS clinic of inner-city hospital. Patients: Patients attending inhaled pentamidine clinic between 1989 and 1991. Intervention: Review of medical records of patients receiving inhaled pentamidine, 300 mg/month, via nebulizer (Respirgard II) as primary or secondary prophylaxis of PCP. Statistical analysis of lymphocyte subset results and selected clinical data. Results: Ten of 57 patients developed PCP during the period of analysis. Patients with CD4 counts less than 60/mm3 were significantly more likely to develop PCP (p=0.01; Fisher's exact test) with a relative risk of 7.55 compared to patients with CD4 lymphocyte counts greater than 60/mm3. Conclusion: Failure of inhaled pentamidine prophylaxis is seen almost exclusively among patients with CD4 lymphocyte counts below 60/mm3.

Original languageEnglish (US)
Pages (from-to)342-344
Number of pages3
Issue number2
Publication statusPublished - Jan 1 1993
Externally publishedYes


ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this